Diagnostic testing in people with primary ciliary dyskinesia: An international participatory study
Diagnostic testing in people with primary ciliary dyskinesia: An international participatory study
Diagnostic tests are important in primary ciliary dyskinesia (PCD), a rare disease, to confirm the diagnosis and characterize the disease. We compared diagnostic tests for PCD between countries worldwide, assessed whether people with PCD recall their tests, and identified factors associated with the use of tests. We used cross-sectional data from COVID-PCD—an international participatory cohort study collecting information directly from people with PCD. The baseline questionnaire inquired about tests used for PCD diagnosis. Using logistic regression, we investigated factors associated with measurement of nasal nitric oxide (nNO), biopsy for electron or video microscopy, and genetic testing. We included data from 747 participants (60% females) from 49 countries worldwide with median age 27 (interquartile range 12–44). Most (92%) reported diagnostic tests for PCD. Participants reported measurements of nNO (342; 49%), biopsy samples (561; 75%), and genetic tests (435; 58%). The reported use of individual tests, such as genetics, varied between countries from 38% in Switzerland to 68% in North America. Participant recall of test type also differed between countries with lowest recall in Switzerland. One-third (232; 36%) of participants reported all three tests (nNO, biopsy, and genetics). Recently diagnosed people reported more tests [nNO odds ratio (OR) 2.2, 95% Confidence Interval (CI) 1.5–3.2; biopsy OR 3.2, 95%CI 2.1–4.9; genetics OR 4.7, 95%CI 3.2–6.9] and those with situs abnormalities fewer tests (nNO OR 0.5, 95%CI 0.4–0.7; biopsy OR 0.5, 95%CI 0.4–0.8; genetics OR 0.7, 95%CI 0.5–0.94). Our results indicate PCD diagnostic testing differed widely around the world and many patients received incomplete diagnostic work-up based only on clinical features or single tests. People diagnosed long ago and those with situs abnormalities possibly benefit from supplementary testing to refine their diagnosis as a prerequisite for personalized medicine.
Schreck, Leonie Daria
cca15dce-a5f6-4efb-9bc7-877291594fd6
Pedersen, Eva Sophie Lunde
bc740384-c2fa-45b6-8d84-701a373d58da
Cizeau, Isabelle
c97a4d99-b94f-440f-bb1e-2795519cca7a
Muller, Loretta
5bbf58e6-64a5-437a-9464-e1d40c9b8363
Kruljac, Catherine
5945baa8-8f18-4903-b524-8276888f013d
Lucas, Jane S.
5cb3546c-87b2-4e59-af48-402076e25313
Goutaki, Myrofora
60fbeefc-dbb1-429c-b81a-3c35d368db64
Kuehni, Claudia E.
ac67c925-ee32-429d-a3b5-c244daa314b4
11 September 2023
Schreck, Leonie Daria
cca15dce-a5f6-4efb-9bc7-877291594fd6
Pedersen, Eva Sophie Lunde
bc740384-c2fa-45b6-8d84-701a373d58da
Cizeau, Isabelle
c97a4d99-b94f-440f-bb1e-2795519cca7a
Muller, Loretta
5bbf58e6-64a5-437a-9464-e1d40c9b8363
Kruljac, Catherine
5945baa8-8f18-4903-b524-8276888f013d
Lucas, Jane S.
5cb3546c-87b2-4e59-af48-402076e25313
Goutaki, Myrofora
60fbeefc-dbb1-429c-b81a-3c35d368db64
Kuehni, Claudia E.
ac67c925-ee32-429d-a3b5-c244daa314b4
Schreck, Leonie Daria, Pedersen, Eva Sophie Lunde, Cizeau, Isabelle, Muller, Loretta, Kruljac, Catherine, Lucas, Jane S., Goutaki, Myrofora and Kuehni, Claudia E.
(2023)
Diagnostic testing in people with primary ciliary dyskinesia: An international participatory study.
PLOS Global Public Health, 3 (9), [e0001522].
(doi:10.1371/journal.pgph.0001522).
Abstract
Diagnostic tests are important in primary ciliary dyskinesia (PCD), a rare disease, to confirm the diagnosis and characterize the disease. We compared diagnostic tests for PCD between countries worldwide, assessed whether people with PCD recall their tests, and identified factors associated with the use of tests. We used cross-sectional data from COVID-PCD—an international participatory cohort study collecting information directly from people with PCD. The baseline questionnaire inquired about tests used for PCD diagnosis. Using logistic regression, we investigated factors associated with measurement of nasal nitric oxide (nNO), biopsy for electron or video microscopy, and genetic testing. We included data from 747 participants (60% females) from 49 countries worldwide with median age 27 (interquartile range 12–44). Most (92%) reported diagnostic tests for PCD. Participants reported measurements of nNO (342; 49%), biopsy samples (561; 75%), and genetic tests (435; 58%). The reported use of individual tests, such as genetics, varied between countries from 38% in Switzerland to 68% in North America. Participant recall of test type also differed between countries with lowest recall in Switzerland. One-third (232; 36%) of participants reported all three tests (nNO, biopsy, and genetics). Recently diagnosed people reported more tests [nNO odds ratio (OR) 2.2, 95% Confidence Interval (CI) 1.5–3.2; biopsy OR 3.2, 95%CI 2.1–4.9; genetics OR 4.7, 95%CI 3.2–6.9] and those with situs abnormalities fewer tests (nNO OR 0.5, 95%CI 0.4–0.7; biopsy OR 0.5, 95%CI 0.4–0.8; genetics OR 0.7, 95%CI 0.5–0.94). Our results indicate PCD diagnostic testing differed widely around the world and many patients received incomplete diagnostic work-up based only on clinical features or single tests. People diagnosed long ago and those with situs abnormalities possibly benefit from supplementary testing to refine their diagnosis as a prerequisite for personalized medicine.
Text
journal.pgph.0001522
- Version of Record
More information
Accepted/In Press date: 7 August 2023
Published date: 11 September 2023
Additional Information:
Funding information:
Our research was funded by the Swiss National Science Foundation (SNSF 320030B_192804/1, recipient CEK) and the Swiss Lung Association (2021-08_Pedersen, ESLP). We also received support from the PCD Foundation, United States (CEK); the Verein Kartagener Syndrom und Primöre Ciliöre Dyskinesie, Germany (CEK); the PCD Support UK (CEK); and PCD Australia, Australia (CEK). MG receives funding from the Swiss National Science Foundation (PZ00P3_185923). Study authors participate in the BEAT-PCD Clinical Research Collaboration, supported by the European Respiratory Society. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Identifiers
Local EPrints ID: 482214
URI: http://eprints.soton.ac.uk/id/eprint/482214
ISSN: 2767-3375
PURE UUID: 5ef93f38-8233-4e59-b1be-a8338c7b2d5a
Catalogue record
Date deposited: 21 Sep 2023 16:46
Last modified: 18 Mar 2024 02:55
Export record
Altmetrics
Contributors
Author:
Leonie Daria Schreck
Author:
Eva Sophie Lunde Pedersen
Author:
Isabelle Cizeau
Author:
Loretta Muller
Author:
Catherine Kruljac
Author:
Myrofora Goutaki
Author:
Claudia E. Kuehni
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
